Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.

NCT04072835 is registered in ClinicalTrials.gov with Milestone Pharmaceuticals Inc. as lead sponsor.

NCT NCT04072835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04072835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.
Lead sponsor
Milestone Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 23, 2019
Completion date
January 26, 2023
Enrollment
1,116 (actual)
Sites
124

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia